This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (9)  • Contact me when this article is cited  Related Content  • Related letter  • Related article  • Similar articles in this journal  Topic Collections  • Venous Thromboembolism  • Alert me on articles by topic

Arch Intern Med. 2002;162:1806-1808.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

VENOUS THROMBOEMBOLISM (VTE) is a common disease, with an average annual incidence of over 1 per 1000.¹ Venous thromboembolism also is a potentially lethal disease, mostly owing to pulmonary embolism (PE). Almost one quarter of all PE cases present as essentially sudden death, with a 1-week survival of only 71%.² Patients with deep vein thrombosis (DVT) often experience serious and costly long-term complications. Almost 30% of patients develop serious venous stasis syndrome within 10 years^3-4 at an estimated cost of over $4000 per episode in 1997 dollars.⁵ To improve survival and prevent complications, the incidence of VTE must be reduced.

Of the total burden of VTE occurring in the community, 50% arises in either hospitalized or recently hospitalized patients.⁶ The incidence of VTE is over 100-fold higher among hospitalized patients compared with community residents.⁷ Of all independent risk factors for VTE, surgery conveys the highest risk,⁸ and major orthopedic leg . . . [Full Text of this Article]

PHARMACOLOGIC PROPERTIES OF FONDAPARINUX AND CLINICAL STUDIES


CONCLUSIONS

RELATED LETTER

Fondaparinux Requires Further Study Before Firm Recommendation
Steven J. Hughes
Arch Intern Med. 2003;163(4):498.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Fondaparinux vs Enoxaparin for the Prevention of Venous Thromboembolism in Major Orthopedic Surgery: A Meta-analysis of 4 Randomized Double-blind Studies
Alexander G. G. Turpie, Kenneth A. Bauer, Bengt I. Eriksson, Michael R. Lassen, and for the Steering Committees of the Pentasaccharide Orthopedic Prophylaxis Studies
Arch Intern Med. 2002;162(16):1833-1840.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Fondaparinux Requires Further Study Before Firm Recommendation
Hughes
Arch Intern Med 2003;163:498-498.
FULL TEXT